Target therapy of the vulvar melanoma based on the genetic study results

Abstract

The article presents two clinical cases of female patients with cancer family history, who have been diagnosed melanoma of the vulva (MV). Using specific PCR and PCR product sequencing, exon 11 KIT gene mutation was detected in tumor biopsy samples obtained from the patients, while BRAF gene mutations were absent. Positive dynamics in response to therapy with tyrosine kinase inhibitor Imatinib (Gleevec) was revealed. During the further treatment in one of the patients a minor NRAS gene mutation was found in metastatic modified inguinal lymph node, indicating a molecular heterogeneity of MV as one of the causes for acquired resistance to targeted therapy.

Keywords

melanoma of the vulva / gene mutation / targeted therapy

References

[1] Raspagliesi F, Ditto A., Paladini D. et al. Prognostic indicators in melanoma of the vulva. Ann. Surg. Oncol. 2000; 7(10): 738-42.

[2] Коржевская Е.В., Кузнецов В.В., Михайлова И.Н. Клинический анализ 38 наблюдений меланомы вульвы. Материалы Российской конференции по онкогинекологии, 8-9 апреля 2009, Москва. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009; 20 (2): 67.

[3] Коржевская Е.В. Новое и старое в лечении меланомы вульвы. Онкогинекология. 2013; 4: 4-9.

[4] Tacastacas J.D., Bray J., Cohen Y.K. et al. Update on primary mucosal melanoma. J. Am. Acad. Dermatol. 2014; 71 (2): 366-75.

[5] Pracht M., Mogha A., Lespagnol A. et al. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucosal melanoma. J. Eur. Acad. Dermatol. Venerol. 2015; doi: 10.1111/jdv 12910.

[6] Abysheva S.N., Ievleva A.G., Efimova N.V. et al. KIT mutations in Russian patients with mucosal melanoma. Melanoma Res. 2011; 21 (6): 555-9.

[7] Omholt K., Grafström E., Kanter-Lewensohn L. et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin. Cancer Res. 2011, 7 (12); 3933-42.

[8] Aullmann S., Sinn H.P., Penzel R. et al. Comparison of molecular abnormalities in vulvar and vaginal melanomas. Mod. Pathol. 2014; doi:10.1038/modpathol. 2013.211.

[9] Carlino M.S., Todd J.R., Rizos H. Resistance to c-Kit inhibitors in melanoma: insights for future therapies. Oncoscience. 2014; 1 (6): 423-6.

[10] Имянитов Е.Н. Меланома: отт исследований молекулярного патогенеза к революции в лечении. Архив патологии. 2013; 75 (5): 63-72.

[11] Демидов Л.В., Утяшев И.А., Харкевич Г.Ю. Роль вемурафениба в лечении диссеминированной меланомы кожи. Современная онкология. 2013; 3: 3-6.

[12] Mehra T., Grozinger G., Mann S. et al. Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. PLoS One. 2014; 9 (11): e 112535.

[13] Fedorenko I.V., Gibney G.T., Smalley S.M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013; 32 (25): 3009-18.

[14] Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M., Smitheman K.N. et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 2012; 11 (4): 909-20.

[15] Todd J.R., Becker T.M., Kefford R.F., Rizos H. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment Cell Melanoma Res. 2013; 26(4): 518-26.

RIGHTS & PERMISSIONS

Eco-Vector